Immunogenicity and Protective Efficacy of Neonatal Vaccination against Bordetella pertussis in a Murine Model: Evidence for Early Control of Pertussis
Open Access
- 1 July 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (7) , 3602-3610
Abstract
A significant resurgence of early cases of pertussis is being observed in infants too young to have yet completed their three-dose vaccination schedule. In this study, murine models of immunization andBordetella pertussischallenge were adapted to early life. This allowed comparative evaluation of immunogenicity and protective efficacy of immunization initiated in the neonatal period (7-day-old mice) or in infancy (3-week-old mice) with diphtheria-tetanus-whole-cell pertussis (DTPw) and diphtheria-tetanus-acellular pertussis (DTPa) vaccines. Neonatal DTPa vaccination induced strong pertussis-specific antibody and memory responses. Patterns of bacterial clearance were similar in both age groups. In contrast, as observed in human neonates, neonatal DTPw priming did not induce significant antibody responses to pertussis toxin (PT) and filamentous hemagglutinin (FHA) and even interfered with subsequent antibody responses. However, this did not reflect induction of permanent neonatal tolerance, as antigen-specific antibodies could be elicited by subsequent exposure to DTPa. Furthermore, despite these blunted PT and FHA antibody responses, the protective efficacy of DTPw in neonatal mice proved similar to that in infant mice, resulting in complete bacterial clearance at day 8 afterB. pertussischallenge. Thus, neonatal priming with antipertussis vaccines should be considered to reduce the window of vulnerability to pertussis at the time of its greatest severity.Keywords
This publication has 40 references indexed in Scilit:
- Hospital admissions for pertussis in Spain, 1995–1998Vaccine, 2001
- Is Pertussis a Frequent Cause of Cough in Adolescents and Adults? Should Routine Pertussis Immunization Be Recommended?Clinical Infectious Diseases, 2001
- Epidemiological Features of Pertussis in Hospitalized Patients in Canada, 1991‐1997: Report of the Immunization Monitoring Program–Active (IMPACT)Clinical Infectious Diseases, 1999
- Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine1Financial support for the present study was provided by the Institut Pasteur Fondation and SmithKline Beecham Biologicals. All animal studies were conducted in accordance with the French and Belgian national legislative guidelines for animal experimentation.1Vaccine, 1999
- Epidemiological, Clinical, and Laboratory Aspects of Pertussis in AdultsClinical Infectious Diseases, 1999
- Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines1All animal studies were conducted in accordance with the French and Belgian national legislative guidelines for animal experimentation.1Vaccine, 1999
- Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccineThe Lancet, 1997
- Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2‐biased pattern which persists after adult boostingEuropean Journal of Immunology, 1996
- Protective efficacy of hepatitis B vaccines in neonatesJournal of Medical Virology, 1994
- The vaccination of the newborn infant against pertussisThe Journal of Pediatrics, 1958